A MedTech startup based in the Middle East had a working prototype and promising early
trials but lacked investor-ready documentation. Despite multiple conversations with
European seed funds, investors struggled to understand the business model and scalability
potential.

What We Did
  • Conducted an intensive discovery exercise to build a clear market thesis highlighting the commercial viability and regional adoption curve.
  • Created a robust financial model with realistic pricing corridors, clinical rollout assumptions, and reimbursement sensitivity analysis.
  • Reworked the pitch deck to focus on patient outcomes, recurring revenue potential, and regulatory advantage.
  • Designed a curated outreach campaign targeting early-stage investors across Europe, including specialized MedTech funds and family offices.
Outcome
  • Within six weeks, the company received 11 investor calls and 2 term sheets.
  • Closed a seed round at a 35 percent valuation premium compared to prior offers.
Key Takeaway

Brisk Capital Services transformed technical validation into financial clarity, enabling the founder to bridge regional capital and international confidence.